Skip to content

CHemical OptImization of Cerebral Embolectomy in patients with acute stroke treated with mechanical thrombectomy 2 (CHOICE2TRIAL)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-504262-32-01
Acronym
CHOICE2
Enrollment
440
Registered
2023-10-19
Start date
2023-11-16
Completion date
2025-11-13
Last updated
2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Embolectomy in patients with acute stroke

Brief summary

Proportion of patients with a mRS 0 to 1 at 90 days.

Detailed description

•Proportion of patients with abnormal microvascular hypoperfusion on CT Perfusion at 36±24h post MT. • Volume of hypoperfusion on brain CTP at 36h±24h post MT •Infarct Expansion Ratio (IER): Final infarct to initial ischemic tissue volumes on brain NCCT at 36±24h post MT. •Barthel Scale score of 95 to 100, at day 90. •Quality of life measured with the EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D-5L) at 90 days. •The shift analysis of the modified Rankin Scale (mRS), at day 90.

Interventions

Sponsors

Foundation Clinic For Biomedical Research
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Proportion of patients with a mRS 0 to 1 at 90 days.

Secondary

MeasureTime frame
•Proportion of patients with abnormal microvascular hypoperfusion on CT Perfusion at 36±24h post MT. • Volume of hypoperfusion on brain CTP at 36h±24h post MT •Infarct Expansion Ratio (IER): Final infarct to initial ischemic tissue volumes on brain NCCT at 36±24h post MT. •Barthel Scale score of 95 to 100, at day 90. •Quality of life measured with the EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D-5L) at 90 days. •The shift analysis of the modified Rankin Scale (mRS), at day 90.

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026